Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

March 16, 2020

Primary Completion Date

January 20, 2021

Study Completion Date

February 20, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Intramuscular other name:Ad5-nCoV

Trial Locations (1)

Unknown

Hubei Provincial Center for Disease Control and Prevention, Wuhan

Sponsors
All Listed Sponsors
collaborator

Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China

OTHER

collaborator

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

collaborator

Hubei Provincial Center for Disease Control and Prevention

OTHER

collaborator

Tongji Hospital

OTHER

lead

CanSino Biologics Inc.

INDUSTRY

NCT04313127 - Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults | Biotech Hunter | Biotech Hunter